ライフサイエンスコーパス: low-density lipoprotein receptor

1 esis, and inhibits cholesterol uptake by the low-density lipoprotein receptor.

2 e expression for lipoprotein lipase and very-low-density lipoprotein receptor.

3 t mice (0.162 cm(2)+/-0.023 [n=9], P2X7(-/-) low density lipoprotein receptor(-/-) : 0.084 cm(2)+/-0.

4 tack complex domain (FIMAC), CD5 domain, and low density lipoprotein receptor 1 (LDLr1) and LDLr2 dom

5 transforming growth factor beta 1, oxidized low-density lipoprotein receptor 1, and C-C motif chemok

6 Lectin-like oxidized low-density lipoprotein receptor-1 (LOX-1) is a pattern-

7 Lectin-like oxidized low-density lipoprotein receptor-1 (LOX-1), one of the s

8 lted in upregulation (~1.5 fold) of oxidized low-density lipoprotein receptor-1 (LOX-1).

9 LOX-1 (lectin-like oxidized low-density lipoprotein receptor-1), a membrane protein

10 Mice deficient for the low-density lipoprotein receptor and Apobec-1 were studi

11 Mice deficient for both the low-density lipoprotein receptor and Apobec-1 were studi

12 CIH down-regulated hepatic low-density lipoprotein receptor and HMG-CoA reductase e

13 Reversa mice, which are deficient in the low-density lipoprotein receptor and in which hyperchole

14 lesterol lowering, with the discovery of the low-density lipoprotein receptor and its physiology and

15 PCSK9, which promotes the degradation of low-density lipoprotein receptors and, therefore, the in

16 role for both a t-PA receptor, most likely a low-density lipoprotein receptor, and a plasminogen rece

17 n that the longer Sepp1 isoforms bind to the low density lipoprotein receptor apoER2, but the mechani

18 ADH is caused by mutations in the low-density lipoprotein receptor, apolipoprotein B, or p

19 screen identified cholesterol uptake by the low-density lipoprotein receptor as essential for the gr

20 che within macrophage by modulating oxidized low-density lipoprotein receptor CD36, phagolysosomal ma

21 atp-binding cassette transporter (atp), and low-density lipoprotein receptor chaperone (ldlr), that

22 forms showed that the amino-terminal modular low-density lipoprotein receptor class A (LA) domains wi

23 e-wide CRISPR-Cas9-based screen, we identify low-density lipoprotein receptor class A domain-containi

24 ucing liver-specific degradation of the LDL (low-density lipoprotein) receptor combined with a 10-wee

25 thylglutaryl-coenzyme A reductase, and human low-density lipoprotein receptor), compared to uninfecte

26 Five-week-old female low-density lipoprotein receptor deficient (LDL-R-/-) an

27 the inflamed aorta in atherosclerosis-prone low-density lipoprotein receptor deficient (Ldlr(-/-)) m

28 bred onto both the Apoe(-/-) and Ldlr(-/-) (low-density lipoprotein receptor deficient) knockout str

29 Moreover, LDLR (low-density lipoprotein receptor) deficient animals tran

30 arrow-restricted deletion of DNGR-1 in Ldlr (low-density lipoprotein receptor)-deficient mice (Ldlr(-

31 y of Nur77 on atherosclerosis was studied in low density lipoprotein receptor-deficient (Ldlr(-/-)) m

32 rom male Flna (o/fl)/ LC mice to atherogenic low-density lipoprotein receptor-deficient ( Ldlr(-/-))

33 Low-density lipoprotein receptor-deficient (Ldlr(-/-) )

34 tic lesions and spleens of high-fat diet-fed low-density lipoprotein receptor-deficient (Ldlr(-/-)) m

35 herosclerotic lesions from high-fat diet-fed low-density lipoprotein receptor-deficient (Ldlr(-/-)) m

36 Lethally irradiated, atherosclerosis-prone, low-density lipoprotein receptor-deficient (Ldlr(-/-)) m

37 Male low-density lipoprotein receptor-deficient (Ldlr(-/-)) m

38 Tet2-mutant cells in atherosclerosis-prone, low-density lipoprotein receptor-deficient (Ldlr(-/-)) m

39 ate senescent cells in atherosclerosis-prone low-density lipoprotein receptor-deficient (Ldlr(-/-)) m

40 od vessels invading photoreceptors: the very low-density lipoprotein receptor-deficient (Vldlr(-/-) )

41 PGES-1-KOs) were crossed into hyperlipidemic low-density lipoprotein receptor-deficient animals.

42 In a low-density lipoprotein receptor-deficient atherosclerot

43 Low-density lipoprotein receptor-deficient chimeric mice

44 Herein, in low-density lipoprotein receptor-deficient hyperlipidemi

45 Low-density lipoprotein receptor-deficient LDLr(-/-) mic

46 the liver of diet-induced insulin-resistant low-density lipoprotein receptor-deficient mice and of g

47 lammation and reduced steatosis in livers of low-density lipoprotein receptor-deficient mice fed a We

48 results in decreased hepatic inflammation in low-density lipoprotein receptor-deficient mice on a Wes

49 ress as prime response pathways in livers of low-density lipoprotein receptor-deficient mice on a Wes

50 luence the development of atherosclerosis in low-density lipoprotein receptor-deficient mice.

51 ions in atherosclerotic aortas obtained from low-density lipoprotein receptor-deficient mice.

52 In the AngII-infused hyperlipidemic low-density lipoprotein receptor-deficient mouse (LDLR(-

53 ux in atherosclerosis-susceptible Ldlr(-/-) (low-density lipoprotein receptor-deficient) mice is subs

54 erosclerosis and insulin resistance in mice, low-density lipoprotein receptor-deficient, S100A9-defic

55 Eight-week-old male low-density-lipoprotein-receptor-deficient mice were sub

56 subtilisin/kexin type 9 (PCSK9) binds to the low-density lipoprotein receptor, escorting it to its de

57 s a result of lower hepatic mRNA editing and low-density lipoprotein receptor expression, and higher

58 element binding protein 2 and downregulating low-density lipoprotein receptor expression.

59 -related protein 1 (LRP1) is a member of the low density lipoprotein receptor family and plays import

60 olecular chaperone that binds LRP1 and other low density lipoprotein receptor family members in the e

61 oprotein receptor (VLDLR) is a member of the low-density lipoprotein receptor family that binds multi

62 -2) is a protein structurally related to the low-density lipoprotein receptor family that displays a

63 Loss-of-function mutations in the LDL (low-density lipoprotein) receptor gene (LDLR) cause elev

64 levels by raising the expression of SREBP2, low-density lipoprotein receptor, HMGCo-A reductase, and

65 nvertase subtilisin kexin 9 (PCSK9) binds to low-density lipoprotein receptors, increasing serum LDL-

66 the in vivo models of C57BL/6 wild-type and low density lipoprotein receptor knock-out (LDLR(-/-)) m

67 when Foxo1(KR/KR) mice are intercrossed with low density lipoprotein receptor knock-out mice (Ldlr(-/

68 of G5-PEG and PB-NLCs were investigated in a low density lipoprotein receptor knockout (LDLr-/-) mous

69 vels by 22 and 31%, respectively, in fasting low-density lipoprotein receptor knockout (LDLR(-/-)) mi

70 Cholesterol-fed low-density lipoprotein receptor knockout (LDLR(-/-)) mi

71 ECGs were measured in low-density lipoprotein receptor knockout (LDLr(-/-)), a

72 in ovalbumin- (OVA-) sensitized C57BL/6 and low-density lipoprotein receptor knockout mice (LDLr(-/-

73 of atherogenesis by mPGES-1 deletion in the low-density lipoprotein receptor knockout mice (n=17-21)

74 In this study, we fed low-density lipoprotein receptor knockout mice a Western

75 Adoptive transfer of apop(ox)-DCs into low-density lipoprotein receptor knockout mice either be

76 and vascular leakage in the eyecups of very low-density lipoprotein receptor knockout mice, a model

77 ncreased atherosclerotic lesion formation in low-density lipoprotein receptor knockout mice.

78 inhibits atherosclerosis development in the low-density lipoprotein receptor knockout mouse.

79 with mPges-1 on a hyperlipidemic background (low-density lipoprotein receptor knockouts).

80 moxifen exerts an atheroprotective action on low density lipoprotein receptor (LDL-r(-/-)) female mic

81 Investigation on the role of low-density lipoprotein receptor (LDL-R) as a hepatocyte

82 K9) down-regulates surface expression of the low-density lipoprotein receptor (LDL-R), increasing ser

83 ls was transplanted into lethally irradiated low density lipoprotein receptor Ldlr(-/-) mice on an at

84 a1(-/-) mice to mice that do not express the low density lipoprotein receptor (Ldlr(-/-)), which are

85 epidermal growth factor-like-A domain of the low density lipoprotein receptor (LDLR) and mediates LDL

86 ted sdAbs efficiently blocked PCSK9-mediated low density lipoprotein receptor (LDLR) degradation in c

87 bind heparin and receptors belonging to the low density lipoprotein receptor (LDLR) family, known to

88 The low density lipoprotein receptor (LDLR) is crucial for c

89 cholesterol regulation through modulation of low density lipoprotein receptor (LDLR) levels.

90 Low density lipoprotein receptor (LDLR) was shown to med

91 To inhibit recognition of oxLDL by KCs, low-density lipoprotein receptor (Ldlr(-/-) ) mice were

92 Mice fed a Western-type diet and lacking low-density lipoprotein receptor (Ldlr(-/-)T39(-/-)) sho

93 because of loss-of-function mutations in the low-density lipoprotein receptor (LDLR) and homozygous f

94 The apoE receptors low-density lipoprotein receptor (LDLR) and LDLR-related

95 a dramatic reduction in transcript levels of low-density lipoprotein receptor (LDLR) and of keratin g

96 The effect of the treatments on cellular low-density lipoprotein receptor (LDLR) and proprotein c

97 fied sulfated glycosaminoglycans (sGAGs) and low-density lipoprotein receptor (LDLR) as host factors

98 in genetically deficient iPSC utilizing the low-density lipoprotein receptor (LDLR) deficiency Famil

99 Female low-density lipoprotein receptor (Ldlr) deficient mice w

100 to adopt active conformations for binding to low-density lipoprotein receptor (LDLR) family.

101 PSCs from JD a patient with mutations in the low-density lipoprotein receptor (LDLR) gene that result

102 le nucleotide polymorphism in exon 12 of the low-density lipoprotein receptor (LDLR) gene, rs688, has

103 which cystathionine beta-synthase (CBS) and low-density lipoprotein receptor (LDLr) genes were defic

104 of cholesterol and an overexpression of the low-density lipoprotein receptor (LDLR) in pancreatic tu

105 Low-density lipoprotein receptor (LDLR) internalization

106 Hepatic abundance of the low-density lipoprotein receptor (LDLR) is a critical de

107 The low-density lipoprotein receptor (LDLR) is a critical de

108 We recently demonstrated that the low-density lipoprotein receptor (LDLR) is a major apoE

109 Therefore, the low-density lipoprotein receptor (LDLR) is a relevant ta

110 Low-density lipoprotein receptor (LDLR) is involved in u

111 ime in atherosclerotic lesion macrophages of low-density lipoprotein receptor (Ldlr) knockout mice fe

112 e crossed Gsk3a/GSK3alpha-knockout mice with low-density lipoprotein receptor (Ldlr) knockout mice.

113 r risk for patients who already have reduced low-density lipoprotein receptor (LDLR) levels, such as

114 The hepatic low-density lipoprotein receptor (LDLR) pathway is essen

115 The low-density lipoprotein receptor (LDLR) plays a pivotal

116 btilisin/kexin type 9 (PCSK9), which reduces low-density lipoprotein receptor (LDLR) recycling and he

117 Low-density lipoprotein receptor (LDLR) rs6511720 A was

118 Since the low-density lipoprotein receptor (LDLR) was recently ide

119 at administering NAPE-expressing bacteria to low-density lipoprotein receptor (Ldlr)(-/-) mice fed a

120 we demonstrate that modulating levels of the low-density lipoprotein receptor (LDLR), a cell surface

121 2 (Dab2) recruits its cargoes, including the low-density lipoprotein receptor (LDLR), and mediates en

122 At low-density lipoprotein receptor (LDLR), carriers of rar

123 at for one of the identified substrates, the low-density lipoprotein receptor (LDLR), ERdj5 is requir

124 audin-1 (CLDN1), Occludin (OCLN), SR-BI, and low-density lipoprotein receptor (LDLR), function mainly

125 tercellular adhesion molecule-1 (ICAM-1) and low-density lipoprotein receptor (LDLR), inter- and intr

126 s, we identified 2 nonsynonymous variants in low-density lipoprotein receptor (LDLR), namely p.G116S

127 ceptor/coreceptor molecules CD81, claudin-1, low-density lipoprotein receptor (LDLr), occludin, and S

128 ertase subtilisin/kexin type 9 (PCSK9) binds low-density lipoprotein receptor (LDLR), preventing its

129 sponsible for the degradation of the hepatic low-density lipoprotein receptor (LDLR), which in turn r

130 As proof-of-principle, we targeted the low-density lipoprotein receptor (Ldlr), which when dele

131 mice, apolipoprotein E (apoE)-deficient and low-density lipoprotein receptor (LDLR)-deficient mice t

132 Low-density lipoprotein receptor (Ldlr)-knockout mice we

133 receptor tyrosine-protein kinase), and Lrp4 (low-density lipoprotein receptor (LDLR)-related protein

134 We previously demonstrated that macrophage low-density lipoprotein receptor (LDLR)-related protein

135 caused by loss-of-function mutations in the low-density lipoprotein receptor (LDLR).

136 e 9 (PCSK9) and regulate its activity on the low-density lipoprotein receptor (LDLR).

137 LDL (low-density lipoprotein) receptor (LDLR) binds to its ne

138 n (MYLIP, aka IDOL and inducible degrader of low-density lipoprotein receptor [LDLR]), with LDL chole

139 th controls, concomitant with an increase in low density lipoprotein receptors (LDLRs).

140 els through a mechanism that is dependent on low-density lipoprotein receptors (LDLRs) and LDLR-relat

141 its role in clathrin-mediated endocytosis of low-density lipoprotein receptors (LDLRs).

142 eased plasma PCSK9 levels, increased hepatic low-density lipoprotein receptor levels, and decreased p

143 Low-density lipoprotein receptors (LRPs) are present ext

144 xpression was analyzed in aortic arches from low density lipoprotein receptor(-/-) mice consuming a h

145 P2X7(+/+) and P2X7(-/-) low density lipoprotein receptor(-/-) mice were fed a hi

146 were transplanted into irradiated recipient low-density lipoprotein receptor(-/-) mice, and atherosc

147 Very low-density lipoprotein receptor mutant mice (Vldlr(-/-)

148 in apolipoprotein-deficient (apoE(-/-)) and low-density lipoprotein receptor negative (LDLR(-/-)) mi

149 Low-density lipoprotein receptor null mice in which Treg

150 METHODS AND Paradoxically, Ldlr(-/-) (low-density lipoprotein receptor null) mice deficient in

151 clerotic lesion size was found in Ldlr(-/-) (low-density lipoprotein receptor null) mice transplanted

152 hages worsened atherosclerosis in irradiated low-density lipoprotein receptor null-recipient mice and

153 Low density lipoprotein receptor-null (Ldlr(-/-)) mice o

154 en by a SM22Cre-IKKbeta-flox system rendered low density lipoprotein receptor-null mice resistant to

155 eficiency on experimental atherosclerosis in low-density lipoprotein receptor-null mice (Ldlr(-/-)).

156 n the vascular smooth muscle lineage of male low-density lipoprotein receptor-null mice, a background

157 APP chimeras harboring targeting motifs from low-density lipoprotein receptor or neuron-glia cell-adh

158 ncrease in permeability, whereas blockade of low-density lipoprotein receptors or exposed lysine resi

159 d via the liver provided that an intact apoE-low-density lipoprotein receptor pathway is present.

160 In parallel, the low-density-lipoprotein receptor plays a predominant rol

161 se subtilisin/kexin type 9 (PCSK9) regulates low density lipoprotein receptor protein levels by diver

162 Low-density lipoprotein receptor protein 1 exerts antiat

163 L mice showed dramatic reductions in hepatic low-density lipoprotein receptor protein and increased p

164 Genetic ablation of Idol increases low-density lipoprotein receptor protein levels, which f

165 ntibodies developed in these mice, LDLR(-/-)/low-density lipoprotein receptor Rag 1 double-knockout m

166 In LDLR(-/-)/low-density lipoprotein receptor Rag 1 double-knockout m

167 IDOL pathway in the liver can override other low-density lipoprotein receptor regulatory pathways lea

168 endent internalization of Abeta bound to the low density lipoprotein receptor related protein-1, a ke

169 complex formation involves Frizzled4 (Fz4), low-density lipoprotein receptor related protein 5/6 (Lr

170 ckkopf2 (Dkk1/2), to their cognate receptor, low-density-lipoprotein-receptor related protein 6 (LRP6

171 Low density lipoprotein receptor-related protein (LRP1)

172 We achieve this by targeting the Low Density Lipoprotein Receptor-Related Protein 1 (LRP-

173 htly to the clearance and signaling receptor low density lipoprotein receptor-related protein 1 (LRP1

174 The low density lipoprotein receptor-related protein 1 (LRP1

175 Low density lipoprotein receptor-related protein 1 (LRP1

176 und that ADAMTS-5 is rapidly endocytosed via low density lipoprotein receptor-related protein 1 (LRP1

177 The low density lipoprotein receptor-related protein 1 (LRP1

178 ndocytic clearance by the scavenger receptor low density lipoprotein receptor-related protein 1 (LRP1

179 ent increases mRNA and protein expression of low density lipoprotein receptor-related protein 2 and a

180 served amino acid position (p.R1188W) in the low density lipoprotein receptor-related protein 5 (LRP5

181 morphogenesis gene 2, as well as coreceptor low density lipoprotein receptor-related protein 6 (LRP6

182 ay genes, such as frizzled homolog 7 (FZD7), low density lipoprotein receptor-related protein 6 and t

183 hosphorylation of eNOS was decreased by anti-low density lipoprotein receptor-related protein-1 (LRP)

184 es, and we found that the endocytic receptor low density lipoprotein receptor-related protein-1 (LRP-

185 We recently identified low density lipoprotein receptor-related protein-1 (LRP1

186 oligomers was dependent on the transmembrane low density lipoprotein receptor-related protein-1 (LRP1

187 The low density lipoprotein receptor-related protein-1 (LRP1

188 ent and activation of beta1 integrin via the low density lipoprotein receptor-related protein-1 (LRP1

189 Soluble low density lipoprotein receptor-related protein-1 (sLRP

190 bind to two distinct receptors, namely, the low-density lipoprotein receptor-related protein (LRP) a

191 Enhanced expression of low-density lipoprotein receptor-related protein (LRP) i

192 We previously reported that RanBP9 binds low-density lipoprotein receptor-related protein (LRP),

193 ng phospholipids, von Willebrand factor, and low-density lipoprotein receptor-related protein (LRP).

194 e largest member of the LDL receptor family, low-density lipoprotein receptor-related protein (LRP1).

195 Blocking low-density lipoprotein receptor-related protein 1 (LRP-

196 We found that an extracellular fragment of low-density lipoprotein receptor-related protein 1 (LRP-

197 Low-density lipoprotein receptor-related protein 1 (LRP-

198 tween BKCaand both alpha2M and its receptor, low-density lipoprotein receptor-related protein 1 (LRP1

199 pericytes also requires the function of the low-density lipoprotein receptor-related protein 1 (LRP1

200 Blocking studies of low-density lipoprotein receptor-related protein 1 (LRP1

201 llaries was associated with its reduction in low-density lipoprotein receptor-related protein 1 (LRP1

202 t portion of apoE and sAbeta compete for the low-density lipoprotein receptor-related protein 1 (LRP1

203 An Abeta clearance receptor, the low-density lipoprotein receptor-related protein 1 (LRP1

204 e has demonstrated significant roles for the low-density lipoprotein receptor-related protein 1 (LRP1

205 Low-density lipoprotein receptor-related protein 1 (LRP1

206 ction with the endocytic scavenger receptor, low-density lipoprotein receptor-related protein 1 (LRP1

207 g internalization of a SNX17 cargo receptor, low-density lipoprotein receptor-related protein 1 (LRP1

208 Low-density lipoprotein receptor-related protein 1 (LRP1

209 , the receptors for these secreted proteins, low-density lipoprotein receptor-related protein 1 (LRP1

210 Here we show that the low-density lipoprotein receptor-related protein 1 (LRP1

211 s isoform-specific interactions of apoE with low-density lipoprotein receptor-related protein 1 on br

212 We hypothesized that LRP1 (low-density lipoprotein receptor-related protein 1) expr

213 ASA-ApoE-II, uptake was partially due to the low-density lipoprotein receptor-related protein 1.

214 se in the brain was impaired in mice lacking low-density lipoprotein receptor-related protein 4 (Lrp4

215 We explored the role of low-density lipoprotein receptor-related protein 4 (LRP4

216 jects have identified autoantibodies against low-density lipoprotein receptor-related protein 4 (LRP4

217 tenance of neuromuscular synapses, and (iii) low-density lipoprotein receptor-related protein 4 (Lrp4

218 inding of y+z+ agrin to both heparin and the low-density lipoprotein receptor-related protein 4 (LRP4

219 Low-density lipoprotein receptor-related protein 4 (Lrp4

220 s anti-osteoanabolic activity is enhanced by low-density lipoprotein receptor-related protein 4 (Lrp4

221 We demonstrate that the low-density lipoprotein receptor-related protein 4 (LRP4

222 ctin, a protein acting downstream from agrin/low-density lipoprotein receptor-related protein 4 (LRP4

223 We identified previously in vitro LRP4 (low-density lipoprotein receptor-related protein 4) as a

224 -derived protein, which interacts with LRP4 (low-density lipoprotein receptor-related protein 4) to a

225 ancer have identified novel functions of the low-density lipoprotein receptor-related protein 4-muscl

226 spectroscopy and show that the co-receptor, low-density lipoprotein receptor-related protein 5 (Lrp5

227 Wnt signaling ligand or receptors, including low-density lipoprotein receptor-related protein 5 (LRP5

228 e human skeleton is affected by mutations in low-density lipoprotein receptor-related protein 5 (LRP5

229 ated the conditional knockout Wnt coreceptor low-density lipoprotein receptor-related protein 5 (Lrp5

230 ptions of tryptophan hydroxylase 1 (Tph1) or low-density lipoprotein receptor-related protein 5 (Lrp5

231 in Lrp5(ACT) mice in which a mutation in the low-density lipoprotein receptor-related protein 5 Wnt c

232 nt signaling, we observed elevated levels of low-density lipoprotein receptor-related protein 5/6 (LR

233 riched around the Wnt-activated Frizzled and low-density lipoprotein receptor-related protein 5/6 rec

234 to determine contributions of Wnt coreceptor low-density lipoprotein receptor-related protein 6 (LRP6

235 The low-density lipoprotein receptor-related protein 6 (LRP6

236 Additionally, inhibition of low-density lipoprotein receptor-related protein 6 (LRP6

237 Low-density lipoprotein receptor-related protein 6 (LRP6

238 a critical chaperone for the Wnt coreceptor low-density lipoprotein receptor-related protein 6 (LRP6

239 Interactions between Cav-1 and low-density lipoprotein receptor-related protein 6 (LRP6

240 ation, where it binds to the Wnt co-receptor low-density lipoprotein receptor-related protein 6 (LRP6

241 quires caveolin-dependent internalization of low-density lipoprotein receptor-related protein 6 (LRP6

242 nin signaling pathway by down-regulating the low-density lipoprotein receptor-related protein 6 (LRP6

243 ical Wnt ligand Wnt3a and the Wnt coreceptor low-density lipoprotein receptor-related protein 6 (LRP6

244 rotein receptor-related protein 5 (Lrp5) and low-density lipoprotein receptor-related protein 6 (Lrp6

245 s duplication in Xenopus embryos, stimulated low-density lipoprotein receptor-related protein 6 (LRP6

246 Low-density lipoprotein receptor-related protein 6 (LRP6

247 t signaling by binding to the Wnt coreceptor low-density lipoprotein receptor-related protein 6 (LRP6

248 Low-density lipoprotein receptor-related protein 6 encod

249 ecific for the E1E2 domain of Wnt coreceptor low-density lipoprotein receptor-related protein 6, Mab2

250 Reduction of frizzleds (fz), arrow (low-density lipoprotein receptor-related protein [LRP] 5

251 itatory synapse number were mediated via the low-density lipoprotein receptor-related protein and sub

252 se domain 9 (ADAM9), reticulon 4 (RTN4), and low-density lipoprotein receptor-related protein associa

253 The low-density lipoprotein receptor-related protein recepto

254 sense substitutions within LRP1B, encoding a low-density lipoprotein receptor-related protein tied to

255 have been reported to be endocytosed by the low-density lipoprotein receptor-related protein-1 (LRP-

256 the neurovascular hypothesis, impairment of low-density lipoprotein receptor-related protein-1 (LRP1

257 Angiopep-2 (ANG), a ligand for the low-density lipoprotein receptor-related protein-1 (LRP1

258 Low-density lipoprotein receptor-related protein-1 (LRP1

259 e N-methyl-d-aspartate receptor (NMDA-R) and low-density lipoprotein receptor-related protein-1 (LRP1

260 ple receptors including mannose receptor and low-density lipoprotein receptor-related protein-1 (LRP1

261 The relationship between low-density lipoprotein receptor-related protein-1 (LRP1

262 (LPS) by a pathway that apparently requires low-density lipoprotein receptor-related protein-1 (LRP1

263 rocytic thrombospondin-1 (TSP1) and synaptic low-density lipoprotein receptor-related protein-1 (LRP1

264 rocytic thrombospondin-1 (TSP1) and synaptic low-density lipoprotein receptor-related protein-1 (LRP1

265 Low-density lipoprotein receptor-related protein-1 (LRP1

266 PDE1C interacts with low-density lipoprotein receptor-related protein-1 and P

267 alytic hemopexin domain of MMP9 binds to the low-density lipoprotein receptor-related protein-1, trig

268 sis and lysosome-dependent degradation in an low-density lipoprotein receptor-related protein-1-depen

269 -dependent PDGFRbeta protein degradation via low-density lipoprotein receptor-related protein-1.

270 n neutrophils and monocytes to MDSCs via the low-density lipoprotein receptor-related protein-2 (LRP2

271 metabolism and insulin sensitivity through a low-density lipoprotein receptor-related protein-2 (LRP2

272 y, we show that Wnt receptors (Frizzled4 and low-density lipoprotein receptor-related protein5 [Lrp5]

273 n (RAP), a ligand-binding antagonist for the low-density lipoprotein receptor-related proteins (LRPs)

274 1 (DKK-1), a ligand for the WNT coreceptors low-density lipoprotein receptor-related proteins 5 and

275 receptors frizzled 1-10 and the co-receptors low-density lipoprotein receptor-related proteins 5 and

276 e frizzled receptor (FZD) and the coreceptor low-density lipoprotein-receptor-related protein 5 (LRP5

277 loci, rs1466535, located within intron 1 of low-density-lipoprotein receptor-related protein 1 (LRP1

278 Fetal liver cells derived from low-density-lipoprotein receptor-related protein 6-defic

279 Here we show that the soluble form of the low-density lipoprotein receptor relative, LR11/SorLA (s

280 via apolipoprotein E receptor 2 and the very low density lipoprotein receptor, resulting in the phosp

281 Drosophila vitellogenin receptor Yolkless, a low density lipoprotein receptor superfamily member, occ

282 teraction with the RELN receptor VLDLR (very low-density lipoprotein receptor); this was confirmed by

283 These antibodies prevent the degradation of low density lipoprotein receptor, thus lowering serum le

284 thereby preventing the recirculation of the low-density lipoprotein receptor to the hepatocyte cell

285 ch region (aa 95-141) that separates the two low-density lipoprotein receptor type A (LDLR-A) domains

286 Activation of very low density lipoprotein receptor (VLDLR) and apolipoprot

287 n signals via the lipoprotein receptors very low density lipoprotein receptor (VLDLR) and apolipoprot

288 polipoprotein E receptor 2 (ApoER2) and very low density lipoprotein receptor (VLDLR) and is internal

289 We discovered that miR-200c targets the very low density lipoprotein receptor (Vldlr) and its ligand

290 ApoE Receptor 2 (ApoER2) and the very low density lipoprotein receptor (VLDLR) are type I tran

291 The very low density lipoprotein receptor (VLDLR) is a member of

292 Previously, we have shown that very low density lipoprotein receptor (VLDLR) is virtually ab

293 ed choroidal neovascularization and the very low density lipoprotein receptor (Vldlr)-knockout mouse]

294 led a point mutation, c.2239C>T, in the very-low-density lipoprotein receptor (Vldlr) gene.

295 The very-low-density lipoprotein receptor (VLDLR) negatively regu

296 thways including through the receptors, Very low-density lipoprotein receptor (Vldlr), Apolipoprotein

297 e deficient in another Reelin receptor, very low-density lipoprotein receptor (VLDLR), had normal rod

298 Very-low-density lipoprotein receptor (Vldlr), which is prese

299 nopathy and another angiogenic model of very-low-density lipoprotein receptor (Vldlr)-deficient (Vldl

300 ion disrupts an interaction with VLDLR (very low-density lipoprotein receptor), while the APOER2 sign